Treatment failures studied in 718 RA pts - csDMARDs D/Cs intolerance (22%), inefficacy (20%), acute Rxns (5%), severe infx(0.6%) - bDMARDs D/Cs inefficacy (29%), intolerance (10%), acute Rxns (6%), severe infx (1.5%) - Multi-drug ifailure 5.7-8.4% https://t.co/FdoP77uELe https://t.co/dQjTNncABc